Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.55 |
| ▸ | SQLE | Q14534 | 7/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | FNTA | P49354 | 1/20 | 0.50 |
| ▸ | FNTB | P49356 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6664660 | 0.83 | KMT2A (0.67) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL28679144 | 0.80 | KMT2A (0.61) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL11529352 | 0.80 | KMT2A (0.61) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL11670568 | 0.80 | KMT2A (0.61) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL4585540 | 0.80 | KMT2A (0.61) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL11620625 | 0.80 | KMT2A (0.61) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL11584608 | 0.79 | KMT2A (0.58) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL11586065 | 0.79 | KMT2A (0.58) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL356392 | 0.79 | KMT2A (0.58) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL23802597 | 0.78 | KMT2A (1.00) | KMT2AMAPTMEN1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083773-A1 | PEGYLATED MENAQUINOL COMPOSITIONS AND METHODS OF TREATMENT | EPIZON PHARMA INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-12514871-B2 | Pegylated menaquinol compositions and methods of treatment | Epizon Pharma, Inc. (US) | 2026-01-06 | — | — | US | disclosed |
| WO-2023235259-A1 | PEGYLATED MENAQUINOL COMPOSITIONS AND METHODS OF TREATMENT | Epizon Pharma, Inc. (US) | 2023-12-07 | — | — | WO | disclosed |
| US-20230381220-A1 | PEGYLATED MENAQUINOL COMPOSITIONS AND METHODS OF TREATMENT | Epizon Pharma, Inc. (US) | 2023-11-30 | — | — | US | disclosed |
| US-11083685-B2 | Methods for treating scars and aging skin | ALLERGAN, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-10398640-B2 | Methods for treating scars and aging skin | ALLERGAN, INC. | 2019-09-03 | — | — | US | disclosed |
| US-20180085392-A1 | CYCLODEXTRIN COMPOUNDS FOR THE PREVENTION AND TREATMENT OF AGING | SENS RES FOUNDATION INC (US) | 2018-03-29 | — | — | US | disclosed |
| WO-2016168772-A1 | CYCLODEXTRIN COMPOUNDS FOR THE PREVENTION AND TREATMENT OF AGING | SENS RESEARCH FOUNDATION, INC. (US) | 2016-10-20 | — | — | WO | disclosed |
| US-20160058816-A1 | METHODS FOR TREATING SCARS AND AGING SKIN | ALLERGAN, INC. | 2016-03-03 | — | — | US | disclosed |
| US-20160058693-A1 | METHODS FOR TREATING SCARS AND AGING SKIN | ALLERGAN INC (US) | 2016-03-03 | — | — | US | disclosed |
| US-9180157-B2 | Methods for treating scars and aging skin | ALLERGAN, INC. | 2015-11-10 | — | — | US | disclosed |
| US-9180158-B2 | Methods for treating scars and aging skin | ALLERGAN, INC. | 2015-11-10 | — | — | US | disclosed |
| US-20130337088-A1 | METHODS FOR TREATING SCARS AND AGING SKIN | ALLERGAN, INC. | 2013-12-19 | — | — | US | disclosed |
| US-8591961-B2 | Aesthetic treatment of scars and aging skin | ALLERGAN, INC. (US) | 2013-11-26 | — | — | US | disclosed |
| US-20120058167-A1 | METHODS FOR TREATING SCARS AND AGING SKIN | ALLERGAN, INC. | 2012-03-08 | — | — | US | disclosed |
| US-20120058076-A1 | AESTHETIC TREATMENT OF SCARS AND AGING SKIN | ALLERGAN, INC. | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180085392-A1 | CYCLODEXTRIN COMPOUNDS FOR THE PREVENTION AND TREATMENT OF AGING | CLN6, GBA2, GLA | KMT2A 4663/4885MAPT 1920/4885MEN1 3599/4885 |
| US-20230381220-A1 | PEGYLATED MENAQUINOL COMPOSITIONS AND METHODS OF TREATMENT | PHOSPHO1, MEN1, MDH2 | KMT2A 1923/4885MAPT 1887/4885MEN1 2/4885 |
| US-20260083773-A1 | PEGYLATED MENAQUINOL COMPOSITIONS AND METHODS OF TREATMENT | SGMS1, SGMS2, MEN1 | KMT2A 1966/4885MAPT 4296/4885MEN1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.